Large Pharmas See China, India, Others As Best Markets, Not U.S.
This article was originally published in PharmAsia News
Executive SummaryThe world's large pharmaceutical companies are looking away from the United States to countries in the developing world such as China and India for major sales growth. More than half of the profits of leading drug makers come from the United States, but emerging markets have made themselves more attractive by offering patent protection and higher individual buying power. Drug makers also express concern a President Barack Obama would engineer a requirement the drug suppliers to the U.S. Medicare system negotiate lower prices. A consultant warns, however, the makers need to have products relevant to patients in the emerging markets. (Click here for more
You may also be interested in...
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.
As part of its response to the coronavirus outbreak, Medicines for Europe has set out a series of policy recommendations that it says could help to mitigate the risks of COVID-19.